Eyeing the 'translatome,' Pfizer ties another knot with biotech partner for preclinical, next-gen targeted therapies

Amber Tong

After closely following eFFECTOR Therapeutics’ work on next-gen targeted cancer therapies in the past two years, chipping in its own venture dollars and inking …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Eyeing the 'translatome,' Pfizer ties another knot with biotech partner for preclinical, next-gen targeted therapies

Amber Tong

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Lower attendance at cell and gene therapy conference mirrors challenged industry

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

Eye­ing the 'trans­latome,' Pfiz­er ties an­oth­er knot with biotech part­ner for pre­clin­i­cal, next-gen tar­get­ed ther­a­pies

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Eyeing the 'translatome,' Pfizer ties another knot with biotech partner for preclinical, next-gen targeted therapies